GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Oncology : An Evidence-Based Approach (2006)
    New York, NY : Springer Science+Business Media, Inc
    Details Availability
    Keywords: Medicine ; Hematology ; Nursing ; Oncology ; Cancer Surgery ; Medicine & Public Health ; Cancer Surgery ; Hematology ; Medicine ; Nursing ; Oncology ; Public health ; Neoplasms ; Medical Oncology ; Survival Rate ; Evidence-Based Medicine ; Onkologie ; Evidenz-basierte Medizin ; Onkologie ; Evidenz-basierte Medizin
    Description / Table of Contents: Oncology: Evidence-Based Approach is a textbook designed to reflect the principles and current practice of oncology with contributors from the fields of medical, surgical, and radiation oncology. The textbook will incorporate an evidence-based approach, enabling the reader to make decisions on the basis of concrete data. Sections on solid tumors, hematologic malignancies and the practice of oncology address the natural history and therapy for the full spectrum of neoplastic diseases in the adult. Further sections present fundamentals of supportive care of the cancer patient, the management of oncologic emergencies and acute toxicities of therapy, as well as care of metastatic disease and the terminally-ill patient. Breaking new ground, the textbook features thoughtful, in-depth sections on cancer prevention and control, cancer surviorship, the economics of cancer care, and cancer informatics. Cancer imaging is covered with an organ system-based approach, with an additional chapter on the especially intriguing potential of PET. Furthermore, a comprehensive section on translational basic science reviews the fundamentals of molecular biology, the cell cycle and signal transduction, carcinogenesis, cancer genetics, the biology of invations and metastasis, and tumor immunology.
    Type of Medium: Online Resource
    Pages: Online-Ressource (XLI, 2005 p, digital)
    ISBN: 9780387310565
    Series Statement: SpringerLink
    URL: https://doi.org/10.1007/0-387-31056-8
    URL: http://dx.doi.org/10.1007/0-387-31056-8
    URL: https://swbplus.bsz-bw.de/bsz280554826cov.jpg
    URL: https://swbplus.bsz-bw.de/bsz121988597kap.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597vlg.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-1.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-2.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-3.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-4.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-5.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-6.htm
    URL: https://swbplus.bsz-bw.de/bsz121988597kap-7.htm
    URL: http://www.gbv.de/dms/bowker/toc/9780387242910.pdf
    DOI: 10.1007/0-387-31056-8
    RVK:
    XH 1200
    Language: English
    Note: Includes bibliographical references and index , Front Matter; Evidence-Based Approach to Oncology; Principles of Chemotherapy; Principles of Radiation Oncology; Principles of Surgical Therapy in Oncology; Principles of Targeted and Biological Therapies; Biologic Principles of Hematopoietic Stem Cell Transplantation; Evaluation of Tumor Markers: An Evidence-Based Guide for Determination of Clinical Utility; Design and Analysis of Oncology Clinical Trials; Ethics of Clinical Oncology Research; Informatics Infrastructure for Evidence-Based Cancer Medicine; Economics of Cancer Care; Principles of Screening for Cancer; Patient Decision Making , Establishing an Interdisciplinary Oncology TeamPrinciples of Complementary and Alternative Medicine for Cancer; Fundamental Aspects of the Cell Cycle and Signal Transduction; Viral Carcinogenesis; Environmental Carcinogenesis; Cancer Metastasis; Tumor Immunology and Immunotherapy; Technologies in Molecular Biology: Diagnostic Applications; Cancer Epidemiology; Evidence-Based Cancer Prevention Research: A Multidisciplinary Perspective on Cancer Prevention Trials; Screening; Genetic Screening and Counseling for High-Risk Populations; Behavior Modification; Central Nervous System Imaging , Breast ImagingImaging of Thoracic Malignancies; Imaging of Gastrointestinal Stromal Tumor; Genitourinary Imaging; Musculoskeletal Imaging; Positron Emission Tomography and Cancer; Central Nervous System Tumors; Eye, Orbit, and Adnexal Structures; Head and Neck Cancer; Lung Cancer; Therapy for Malignant Pleural Mesothelioma; Mediastinum; Esophageal Cancer; Stomach; Colon, Rectal, and Anal Cancer Management; Adenocarcinoma and Other Small Intestinal Malignancies; Cancer of the Liver and Bile Ducts; An Evidence-Based Approach to the Management of Pancreatic Cancer; Renal Cell Cancer , Ureter, Bladder, Penis, and UrethraProstate Cancer; Testis Cancer; Cervix, Vulva, and Vagina; Gestational Trophoblastic Neoplasia; Ovarian Cancer; Uterine Malignancies; Evidence-Based Management of Breast Cancer; Thyroid and Parathyroid; Tumors of the Endocrine System; Sarcomas of Bone; Soft Tissue Sarcoma; Cutaneous Melanoma; Nonmelanoma Cutaneous Malignancies; Cancer of Unknown Primary Site; Solid Tumors of Childhood; Acute Myeloid Leukemia and the Myelodysplastic Syndromes; Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia and Related Chronic Leukemias; Chronic Myeloid Leukemia , An Evidence-Based Approach to the Management of Hodgkin's LymphomaThe Non-Hodgkin's Lymphomas; Multiple Myeloma; Superior Vena Cava Syndrome; Central Nervous System Emergencies; Metabolic Emergencies in Oncology; Surgical Emergencies; Oral Complications of Cancer Therapy; Alopecia and Cutaneous Complications of Chemotherapy; Infectious Complications of Cancer Therapy; Acute Toxicities of Therapy: Pulmonary Complications; Cardiac Complications; Neurologic Complications of Therapy; Acute Toxicities of Therapy: Urologic Complications , Issues in Vascular Access with Special Emphasis on the Cancer Patient
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    GEOMAR CATALOGUE
    Link to Library Catalog
    get availability status
  • 2
    Electronic Resource
    Electronic Resource
    Coordination complexes and catalytic properties of proteins and related substances. 87. Methylation of glucagon, characterization of the sulfonium derivative, and regeneration of the native covalent structure (1977)
    s.l. : American Chemical Society
    Biochemistry 16 (1977), S. 5813-5818 
    Details
    ISSN: 1520-4995
    Source: ACS Legacy Archives
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1021/bi00645a027
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Tamoxifen-induced Radiation Recall Dermatitis (2004)
    Oxford, UK : Blackwell Science Inc
    The @breast journal 10 (2004), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1075-122X.2004.21222.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Improving Hormonal Therapy for Breast Cancer (1997)
    Oxford, UK : Blackwell Publishing Ltd
    The @breast journal 3 (1997), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: Since Beatson's observation of breast cancer regression after oophorectomy one hundred years ago (1), therapies directed toward the estrogen-estrogen receptor (ER) endocrine axis have become a cornerstone of breast cancer treatment. Surgical ablative techniques, such as oophorectomy, adrenalectomy, and hypophysectomy have been largely replaced by pharmacological approaches that inhibit estrogen-dependent breast cancer growth, either by reducing estrogen synthesis (LHRH agonists, aromatase inhibitors, and progestins), by blocking ER function (tamoxifen) or by interfering with the cellular response to ER activation (androgens). Indeed, one could argue that hormone therapy for breast cancer represents one of the most successful areas of logical drug design in cancer treatment. Recent drug developments have led to improved side-effect profiles for hormonal agents. In addition, the remarkable organ-selective agonist/antagonist properties of tamoxifen-related compounds are the basis for an effort to develop hormone replacement therapies that combine breast cancer treatment/prevention with reduced osteoporosis and heart disease risk. While the ER axis will remain a primary focus for the further development of hormonal therapies (Table 1), the value of ER as a therapeutic target will always be limited by the primary or acquired estrogen insensitivity that nearly all breast cancers ultimately display. Current hopes for circumventing this problem lie in the vast therapeutic potential afforded by recent molecular insights into growth regulatory pathways. Logical choices for novel therapeutic targets for “estrogen insensitive” breast cancer includes alternative nuclear hormone receptors, growth factor receptors, and signal transduction molecules in “ER-independent” growth-regulatory pathways. Inhibitors of pathophysiological processes intrinsic to tumor progression, such as angiogenesis, invasion, and metastasis are also promising noncytotoxic alternatives in breast cancer therapy (Table 2). Studies of growth regulators in breast cancer are also likely to lead to new tumor markers to accurately guide choices from the increasing array of therapeutic options available.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1524-4741.1997.tb00209.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients (1999)
    Boston, MA, USA : Blackwell Science Inc
    The @breast journal 5 (1999), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: ▪ Abstract: After clinical staging, the single most important prognostic factor for patients with newly diagnosed primary breast cancer is the presence or absence of detectable metastases to axillary lymph nodes when examined by conventional light microscopy. More sensitive methods of determination of lymph node status, such as evaluation of serial sections, immunohistochemical staining, and use of molecular biological assays increase the rate of detection of micrometastases. Although the feasibility of enhanced detection of occult axillary metastatic disease is well established, the prognostic significance of such detection is only recently starting to emerge. Furthermore, the enormous recent interest in the application of sentinel lymph node biopsy as an alternative to the evaluation of the entire axilla in patients with breast cancer makes the first-time detailed evaluation for micrometastases practically feasible. In this review the different methods of detecting micrometastatic disease in the axilla and the significance of such findings are discussed. ▪
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1524-4741.1999.99053.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Primary Chemotherapy of Resectable Breast Cancer (1995)
    Oxford, UK : Blackwell Publishing Ltd
    The @breast journal 1 (1995), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: Primary chemotherapy (the administration of chemotherapy prior to definitive locoregional therapy) of breast cancer has numerous potential advantages and several identified disadvantages. While primary chemotherapy has been used widely in the treatment of locally advanced and inflammatory breast cancers, interest is now turning to its use in resectable breast cancers. Within the last five years, several trials of primary chemotherapy in the treatment of resectable breast cancer, both randomized and non-randomized, have been published. Although preliminary reports suggest that primary chemotherapy may be advantageous, the results from definitive randomized trials are not yet available. Until they are, this approach, although promising, remains in the investigational stages.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1524-4741.1995.tb00217.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells (1996)
    [s.l.] : Nature Publishing Group
    Nature medicine 2 (1996), S. 1367-1370 
    Details
    ISSN: 1546-170X
    Source: Nature Archives 1869 - 2009
    Topics: Biology , Medicine
    Notes: [Auszug] Given the plethora of well–documented breast carcinoma–associated antigens in humans including MAGE–1, –2 and –3, mutated p53, p21ras, HER–2/neu and DF3/MUC–1, coupled with evidence that humoral and cytotoxic T–cell responses against these antigens ...
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1038/nm1296-1367
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer (1999)
    Springer
    Cancer chemotherapy and pharmacology 43 (1999), S. 68-72 
    Details
    ISSN: 1432-0843
    Keywords: Key words Vinorelbine ; Breast cancer ; Phase I ; Dose intensity ; Growth factor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: Vinorelbine (Navelbine) is a semisynthetic vinca alkaloid with documented activity in breast cancer. The major dose-limiting toxicity (DLT) when given weekly is myelosuppression with minimal neurologic toxicity. This phase I study attempted to define the maximally tolerated dose (MTD) and the DLT of vinorelbine on a daily ×3 schedule with and without filgrastim support. Methods: A total of 19 patients with stage IV breast cancer were enrolled in separate studies at Duke University Medical Center (DUMC) and the Dana-Farber Cancer Institute (DFCI). Eligible patients could have received up to two prior chemotherapy regimens in the metastatic setting and had to have an ANC 〉1500/mm2, PLT 〉100 000 m3, creatinine 〈2.0 mg/dl, bilirubin 〈2.0 mg/dL, SGOT not more than three times normal, and performance status 0–1. Vinorelbine was administered using a daily ×3 schedule every 3 weeks. The protocols were designed to study dose escalation with and without growth factor support. At DUMC, in the initial phase of the study, the starting dose was 15 mg/m2 per day and dose escalations of 5 mg/m2 were planned until DLT developed and the MTD was defined. DLT was defined as granulocytopenia 〈500/mm3 for 〉7 days, grade IV thrombocytopenia, febrile neutropenia, or grade III or greater nonhematologic toxicity. In the second phase of the study, growth factor support was given with vinorelbine at the MTD. Filgrastim at a dose of 5 g/kg was started on day 4 of the 21-day cycle and was continued until the neutrophil count exceeded 10 000 cells/mm3. At DFCI, all patients received growth factor starting on day 4 and the starting dose of vinorelbine was 25 mg/m2. Results: At DUMC, DLT was seen at 20 mg/m2 in three of three patients and included febrile neutropenia, grade IV neutropenia 〉7 days, grade III neurotoxicity, and grade III vomiting. Despite the addition of filgrastim, DLT was again seen at 20 mg/m2 and included grade III neurotoxicity (jaw pain, abdominal pain, constipation, ileus) and grade IV mucositis. Three patients at DFCI were treated with vinorelbine at a dose of 25 mg/m2 with growth factor support, and two developed DLT including febrile neutropenia, neutropenia 〉7 days, and grade III stomatitis. Conclusions: Our effort to escalate the dose intensity of vinorelbine on this schedule was not successful and was complicated by hematologic and nonhematologic toxicity. A daily ×3 schedule of vinorelbine should not be pursued as an alternative treatment regimen in patients with previously treated metastatic breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800050864
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Doxorubicin for inflammatory breast cancer: A red humor for a red tumor? (1995)
    Springer
    Annals of surgical oncology 2 (1995), S. 283-285 
    Details
    ISSN: 1534-4681
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02307057
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? (1998)
    Springer
    Breast cancer research and treatment 52 (1998), S. 305-319 
    Details
    ISSN: 1573-7217
    Keywords: tumor markers ; prognostic factors ; predictive factors ; breast cancer ; patient management ; treatment decisions
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Very few tumor markers have been recommended for routine clinical care of patients with breast cancer [1]. A framework to determine the clinical utility of tumor markers is required. In a previous publication, a "Tumor Marker Utility Grading System" (TMUGS) was proposed [2]. TMUGS included a semi-quantitative grading scale (0-3+) which can be used to assign a score to a given tumor marker for a given outcome. Only those markers that are felt to be sufficiently strong to influence a therapeutic decision that results in improved clinical outcome for the patient are recommended. The studies from which data are used to assign a TMUGS grade can be placed into one of five Levels of Evidence (LOE). An extension of TMUGS ("TMUGS-Plus") is now proposed in which the relative strength of a prognostic or predictive factor can be estimated and expressed in terms of a risk ratio (RR) for prognostic factors or benefit ratio (BR) for predictive factors. Three categories of prognostic factors and three categories of predictive factors are proposed (strong, moderate, and weak). It is recommended that only LOE type I studies (prospective, highly powered studies of the tumor marker, or meta-analysis of LOE II or III datasets), be used to estimate the RR or BR of a given factor. Finally, a matrix, based on assumptions of acceptable absolute benefits relative to risks, is proposed in which any given tumor marker can be assessed for its clinical utility. TMUGS-Plus should aid in the assessment of published data regarding clinical utility of tumor markers. Perhaps more important, clinical investigators can use TMUGS-Plus to design tumor marker studies that will fulfill criteria for clinical utility, resulting in more rapid acceptance of tumor markers for routine clinical use.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006197805041
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...